Exec Chat: KCI CEO Andrew Eckert Foresees Big Year For Wound-Care Company
Since selling its LifeCell aesthetic and surgical products business to Allergan in early 2017, Acelity has refocused its commercial efforts, and its name, on the KCI wound-care business, with significant investments in medical education, clinical studies and R&D in that sector, as well as the recent acquisition of UK-based Crawford Healthcare.
You may also be interested in...
Acelity has agreed to acquire Crawford Healthcare for an undisclosed price to expand its wound care portfolio. Crawford's wound-dressing portfolio includes the KerraMax Care, KerraFoam, and KerraCel brands, complementing Acelity's advanced wound dressing line-up, which includes the Promogran Prisma Matrix collagen dressing, the Tielle dressings, and Adaptic dressings. The deal also includes Crawford's research and development and manufacturing facilities in Chesire, UK.
In a bid to counter increasing pressure on its core negative pressure wound care business, Kinetic Concepts is expanding its portfolio by agreeing to buy UK firm Systagenix for $485m. The deal, which is expected to close in the fourth quarter, is a “major step…towards increased revenue diversification and geographic expansion,” Kinetic said.
News We're Watching: GE, Biofourmis Partnership, Tricuspid Procedure Boom, Boston Scientific Borrows $2Bn, And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, GE Healthcare and Biofourmis announced a deal to collaborate on virtual care; Cleerly touts a new CPT code for its Ischemia cardiac diagnostic software; Boston Scientific announced how it plans to pay for Axonics; a Wells Fargo survey suggests the market for transcatheter tricuspid valve repair and replacement will grow faster than previously imagined; Virtual Incision earns FDA de novo authorization for its MIRA miniaturized surgical system for colectomy procedures; and MMI and Fabric announce major financing rounds.